Sildenafil citrate therapy for pulmonary arterial hypertension.

By N. Galiè, H. Ghofrani, A. Torbicki, R. Barst, L. Rubin, D. Badesch, T. Fleming, T. Parpia, G. Burgess, A. Branzi and 3 more. New England Journal of Medicine, 2005

2,222 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/68a9e94416ee1a8d0adcb6fde0d03b9c06e5c5a9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

G. Simonneau

Citations in the corpus

Riociguat for the treatment of pulmonary arterial hypertension. (2013, neutral): “Associated with congenital heart disease 12 (10) 15 (6) 8 (13) 35 (8)”
Pulmonary arterial hypertension (2013, background): “Long term extension data from 222 patients who completed one year of sildenafil monotherapy with a dose of 80 mg three times daily showed encouraging results with a gain in 6-MWD, suggesting a durable treatment effect [236].”
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond (2006, background): “Additionally, patients completing the double-blind phase were able to enter a long-term extension trial, which was conducted over a 2-year period with 80 mg sildenafil TID.”
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. (2006, background): “A large, randomized, placebo-controlled trial with the oral phosphodiesterase inhibitor sildenafil has also demonstrated improvements in symptoms, exercise capacity, and hemodynamics (14).”
Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. (2010, background): “Medications that can lower pulmonary vascular resisance (PVR) and the improve cardiac index before surery may be beneficial in reducing the incidence of RV ailure after implant.(44,45) Medications that have been hown to reduce PVR include angiotensin-converting enyme (ACE) inhibitors, hydralazine, n”